PDCD1 and lung cancer: The results show that in 1st line (HR 0.74, 95% CI 0.61-0.90, p = 0.003, Fig. 7a), anti-PD-1 (control group) (HR 0.90, 95% CI 0.84-0.98, p = 0.01, Fig. 7c), anti-CTLA-4 (control group) (HR 0.76, 95% CI 0.66-0.86, p < 0.0001, Fig. 7e), melanoma (HR 0.74, 95% CI 0.61-0.90, p = 0.003, Fig. 7f) and lung cancer (HR 0.89, 95% CI 0.81-0.98, p = 0.02, Fig. 7g) groups, the PFS of ICI combination therapy was significantly longer than that of ICI monotherapy.